Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Turn Therapeutics Inc.NASDAQ: TTRX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation of $0 in Q1 FY2026
Q1 FY2026 stock-based compensation was $0. Trailing-twelve-month stock-based compensation was $0.
Context
- Stock-based compensation increased in 1 of the last 2 fiscal years.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 419.25K USD
- Year-over-year change
- +18.8%
- 2-year CAGR
- -19.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 419.25K | +18.8% |
| FY2024 | 2024-12-31 | 352.83K | -44.9% |
| FY2023 | 2023-12-31 | 640.26K | — |
Stock-Based Compensation vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 stock-based compensation of $0 is the smallest of the 9 companies compared; the peer median is $4.82M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.83M | +85.9% | +222.1% | — | |
| LTM Mar 2026 | $12.88M | -49.1% | -22.9% | 85.6% | |
| LTM Mar 2026 | $10.29M | -14.6% | -1.8% | 8.3% | |
| LTM Mar 2026 | $5M | — | +208.8% | — | |
| LTM Mar 2026 | $4.63M | -43.5% | +57.4% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $3.95M | +20.1% | +23.4% | 33.0% |
| LTM Apr 2026 | $2.26M | -44.4% | -15.0% | — | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TTRX) | $4.82M | -42.1% | +10.8% | 33.0% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 640.26K | 352.83K | 419.25K |
| Change in Working Capital | 229.74K | (1.86K) | 2.37M |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 2.26M |
| Other Working Capital | 229.74K | (1.86K) | 105.03K |
| Other Non-Cash Items | 662 | 8.65K | (2.21M) |
| Operating Cash Flow | (1.38M) | (1.36M) | (2.56M) |
| Capital Expenditures | (44.31K) | (99.48K) | (152.99K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (152.99K) |
| Investing Cash Flow | (44.31K) | (99.48K) | (152.99K) |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 500K | 1.15M | 6.92M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 500K | 1.15M | 6.92M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (921.99K) | (308.4K) | 4.2M |
| Free Cash Flow | (1.42M) | (1.46M) | (2.72M) |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.